Novavax - Google Search

table,div,span,p{display:none}Please click here if you are not redirected within a few seconds.

AllNewsImages Videos Maps Books

Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company's non-mRNA COVID-19 vaccine is approved,...
1 day ago

Novavax Shares Cut to Underperform by Bank of America on Growth Concerns

Bank of America lowered its rating on Novavax to Underperform from Neutral, citing mounting questions about the vaccine maker's long-term...
6 hours ago

Novavax downgraded to Underperform at BofA on growth uncertainties

Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more here.
7 hours ago

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Novavax Investor Relations

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in...
2 months ago

FDA approves Novavax COVID-19 shot but with unusual restrictions

The Food and Drug Administration has issued a long-awaited approval of Novavax's COVID-19 vaccine but with unusual restrictions.
3 months ago

Nu double upgraded, Novavax downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that...
7 hours ago

FDA approves full license for Novavax's COVID vaccine

The US Food and Drug Administration (FDA) has approved full licensure for its COVID-19 vaccine, Nuvaxovid, which had been used since July 2022 under an...
3 months ago

Novavax banks on vaccine supply partnerships to boost 2025 revenue

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with...
2 weeks ago

BofA Downgrades Novavax to Underperform From Neutral, Adjusts Price Target to $7 From $9

Novavax has an average rating of hold and mean price target of $12.86, according to analysts polled by FactSet. Price: 8.93, Change: -0.59,...
7 hours ago

Novavax downgraded to Underperform at BofA on ‘murky outlook’

As previously reported, BofA downgraded Novavax (NVAX) to Underperform from Neutral with a price target of $7, down from $9,...
10 hours ago